ABSTRACT
INTRODUCTION
Chronic pain is highly correlated with sleep disturbance. [1] [2] [3] The incidence of disturbed sleep in participants with arthritis is estimated at nearly 60 percent. [4] [5] [6] Importantly, baseline pain levels may even be predictive of sleep difficulties up to two years in the future. 4 Furthermore, the relationship between disturbed sleep and pain appears to be bidirectional: pain worsens sleep difficulties and poor sleep heightens the perception of pain. [7] [8] [9] Increasing pain levels may be correlated with an increasing risk for insomnia, 2 and recurrent poor sleep may be linked to muscular pain, tenderness, and fatigue. 7, 8 Opioids are a commonly used pharmacological tool for the management of chronic to moderate to severe pain. Yet, there have been relatively few studies using objective sleep measurements to evaluate the effects of these medications on any participants, much less chronic pain participants. A publication of a limited study suggests that acute nighttime (presleep time) administration of opioids may suppress rapid eye movement (REM) sleep and slow wave sleep and may unexpectedly increase wakefulness. 10 On the basis of this limited experience related to acute administration, it might be speculated that in chronic pain participants opioid medications given to alleviate pain could in fact be disruptive to sleep and could contribute to the participant's sleep disturbance, rather than ameliorating it. Studies by Caldwell et al., 11 Rauck et al., 12 and Panjabi et al. 13, 14 are in contrast to this, where osteoarthritis participants stated, in selfadministered questionnaires, that pain relief with opiates improved the quality of their sleep.
The use of sustained release opioids (SROs) may be responsible for the improvements in sleep as found by Caldwell, Rauck, and Punjabi. The pharmacokinetics and analgesic properties of a given SRO are highly dependent on the release profile of the drug delivery system. Therefore, two different modified-release formulations of the same opioid may yield significantly different profiles, even when administered in a similar manner.
Release of morphine sulfate (A-MQD) is a morphinebased SRO with a novel modified-release formulation specifically designed for once-daily dosing. 11 The present exploratory study was designed to determine whether alleviation of chronic pain in osteoarthritic participants via A-MQD would produce concurrent improvements in polysomnographic (PSG) sleep measures in addition to confirming prior reports of subjective sleep improvement. Correlation of PSG findings with measures of neurocognition as well as quality of life measures was also assessed.
METHODS

Study design
This single-center, placebo-lead-in, single-treatment, single-blind study was conducted at a US site. Two doses (30 mg, titrated to 60 mg as needed for a subset of the population) of A-MQD were evaluated in participants with documented osteoarthritis complaining of sleep disturbances secondary to their osteoarthritic pain. The protocol for this study was approved by an institutional review board, and the study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines.
Participant selection involved three screening steps ( Figure 1 ). First, potential participants underwent a clinical assessment visit. Second, participants returned for a polysomnographic screening visit (screening) while continuing the participants' then current pain therapy. Third, participants who continued to be eligible were then withdrawn from their current pain and sleep medication during a fiveday single-blind placebo-washout period that concluded with two nights of PSG evaluation (baseline). Subjective and neurocognitive evaluations were performed prior to discharge on the second morning (baseline for these evaluations). At this point, to continue to be eligible, participants had to have a score of ³ 4 on the Brief-Pain-Inventory (BPI).
Participants who passed these three screening evaluations were formally entered into the study and were then provided with 14 days of active treatment (30 mg/d A-MQD). Participants returned to the clinic on the sixth day of active treatment to repeat the series of subjective and neurocognitive tests performed at placebo baseline. At this visit, the dose of A-MQD was increased to 60 mg/d for participants reporting inadequately responsive pain. Participants returned to the clinic on the thirteenth-and fourteenth-day of treatment for a final two nights of PSG evaluation (day 13/14). Again, the subjective and neurocognitive batteries were repeated and final safety evaluations were performed prior to the final discharge on day 15.
As this was a pilot study, part way through the study, an interim analysis was conducted to examine the internal consistency of the data. This analysis suggested (see discussion section) that the two treatment arms (30 mg/d for 14 days vs 30 mg/d for six days followed by eight days at 60 mg/d) did not represent comparable exposure to constant doses of study drug. At this point, participants whose dosage had been increased to 60 mg/d were provided with treatment at this dose level for a further full 14 days, thus spending a total of 20 days on study treatment. Participants in this last group did not repeat the day 6 assessments after six days at the new dose level and engaged in the final PSG evaluations on day 19 and 20 (equivalent to day 13/14 for the other groups) and the final subjective assessments on day 21 (equivalent to day 15 for the other groups).
Regardless of treatment arm, concomitant medication was restricted. Both prescription and OTC pain and sleep medications were prohibited. In addition, the use of any form of steroids and viscosupplementation in osteoarthritic joints was not allowed. Rescue medications for either pain or sleep were not allowed.
Subject recruitment and selection
Male and female participants with osteoarthritis at a hip and/or knee joint, aged 18 to 80, in relatively good health were recruited for this study through local physicians and newspaper advertisements. Participants were eligible if they reported sleep disturbances secondary to their osteoarthritic pain and had been taking NSAIDs, acetaminophen, and/or a prn analgesic containing an opioid (maximum of 30 mg/d in morphine equivalents) for at least three months. Participants were further required to 1) not have a diagnosis of any chronic pain syndrome that would interfere with the assessment of osteoarthritis symptoms, 2) not have prior replacement surgery or other clinically significant disease at the affected joint(s), 3) not have a history of substance abuse or dependence, and 4) not receive any steroids within 30 days prior to baseline assessments, intra-articular steroids in within 60 days prior to study baseline, or intra-articular viscosupplementation at the affected joint(s) within six months of the start of the study.
After signing an informed consent statement, prospective study participants underwent a screening process that included a physical examination, clinical laboratory tests, and a 12-lead ECG. Qualified participants were invited to undergo a PSG screening night while continuing their current pain therapy. Participants who met the screening criteria for other sleep disorders (i.e., sleep apnea, periodic limb movement disorder) during the PSG screening night were no longer eligible for participation.
Next, eligible participants underwent a five-day placebo washout from all pain and sleep medications. At this point (placebo baseline), participants were finally invited to enter into a single-blind treatment if they had an average pain rating of ³ 4 on the BPI scale.
Study procedures
Study drug. A-MQD (30 and 60 mg/d) was evaluated in this study. Medication (30 mg/d) was dispensed to participants after a single-blind placebo-baseline PSG night followed by next-morning neurocognitive, subjective pain, and sleep assessments. Participants were educated on the possible side effects of the study medication and cautioned about drowsiness while driving. They were then instructed to swallow one capsule of study medication in the morning each day for the next 14 days. Participants complaining of inadequate pain relief were titrated to 60 mg/d at the day 6 visit.
Polysomnography. PSG recordings were performed by experienced technicians and were scored according to the methodology of Rechtschaffen and Kales 15 by a single registered polysomnographic technologist. Scoring was later confirmed by a blinded external, accredited polysomnographer. Recordings were taken in the sleep laboratory at screening (day -6, -5), baseline (day -2, -1), and during treatment (day 13, 14) for a period of 480 minutes with lights out beginning at the participant's habitual bedtime. PSG values are the mean of each two-night period.
Subjective assessments. Participants completed several subjective assessments of their sleep and pain. These evaluations were completed at screening (day -5), baseline (day 0), and during treatment (day 6, 15) and included the Epworth Sleepiness Scale (ESS), a sleep quality questionnaire, the Brief Pain Inventory (BPI), and ratings of the acceptability of and relief provided by their current therapy. The ESS is an eight-question instrument that assesses the participant's subjective sense of the likelihood of falling asleep in various real-life situations. Each question is rated on a scale of 0 ("would never doze") to 3 ("high chance of dozing"). The sleep quality questionnaire asked participants to rate their quality of sleep on a VAS scale of 0 to 100 and to estimate the average number of hours of sleep they were getting per night. The BPI is a series of questions in which participants rate their pain on a scale of 0 ("no pain") to 10 ("pain as bad as you can imagine"). Participants used a five-point scale to rate their acceptance of their current therapy. This scale was anchored at 0, "none" and 4, "excellent." Finally, participants used a five-point scale anchored at 0, "none" and 4, "complete" to indicate the pain relief provided by their current therapy.
Neurocognitive battery. The neurocognitive battery was performed by a psychologist (SB) at screening (day -5), baseline (day 0), and during treatment (day 6, 15 Compliance. At each visit, participants were monitored for drug compliance and had to have taken at least 85 percent of the prescribed doses to be considered compliant. During the first week of treatment, if a participant missed ³ one day of dosing or took > seven capsules during any seven-day period, he or she was instructed on the proper dosing and the importance of maintaining the dosing schedule. If the participant continued to be noncompliant, he or she was dropped from the study.
Safety evaluations
Vital signs were recorded at screening and at each visit during treatment. A physical examination along with chemistry and hematology was performed at screening and prior to discharge at the last study visit. A 12-lead ECG was also obtained at screening. Adverse event information was collected at each visit.
Data analysis
The efficacy endpoints were analyzed for compliant study participants who completed at least the day 6 evaluations (e.g., the evaluable population). The safety analysis was performed for all participants who were exposed to at least one dose of study medication. Parameters measured on more than one day (e.g., days 13 and day 14) during the screening, baseline, or treatment periods were defined as the average of the values obtained at each measurement period. Changes from baseline values were calculated both as a percent-change-from-baseline and as an absolute-change-from-baseline. Changes from screening were calculated as an absolute-change-frombaseline only. Nonparametric statistical methods (e.g., Wilcoxon tests) were used. Hypothesis testing was twosided and claims of significance were based on two-sided p-values of p-values of 0.05 or less.
RESULTS
Demographics
A total of 127 participants were screened. Of these, 93 did not progress to treatment because they failed the inclusion/exclusion criteria. No participant dropped out of the screening process because of inadequately controlled pain during the placebo washout period. Thus, 34 progressed to receive treatment (e.g., intent-to-treat population) and 31 participated for long enough to be considered evaluable. The demographics of the participants who completed the study include a mean age of 53. Participants who received 30 mg/d of A-MQD for the entire study period will be referred to as the "30 mg ´14 day group," participants whose dosage was increased to 60 mg/d after the first six days of treatment will be referred to as the "60 mg ´8 day group," and participants whose dosage was increased to 60 mg/d and who continued with treatment for a full 14 days at this level will be referred to as the "60 mg ´14 day group." Day 13/14 and day 15 values refer to day 19/20 and day 21 values, respectively, for this latter group.
As mentioned earlier, the interim analysis suggested that the study results for the 30 mg ´14 day group and the 60 mg ´8 day group would not represent comparable periods of uniform exposure to study drug. Thus, the rest of this document will largely focus on the results for the 30 mg ´14 day group and the 60 mg ´14 day group. The results for the 60 mg ´8 day group are included in the appropriate tables, but will not be discussed further.
Polysomnography
Given the relatively small size of the study population, measures of sleep continuity initiation, maintenance, and architecture are presented for the participant population as a whole and as a function of dose groups (Table 1 and Figures 2 to 4) .
Compared with normal sleepers, the sleep architecture of the study population at screening reflected their sleep disturbances (increased sleep stage 1 [data not shown]; diminished sleep stages 2 and 3/4; longer REM latency), even while stable on prior pain therapy. At baseline, subsequent to the withdrawal of all pain medications, some of these differences were attenuated suggesting that the participants' previous therapies were negatively affecting their sleep (Table 1) . Overall, compared with baseline, treatment with A-MQD preserved sleep architecture and tended to increase stage 2 and stage 3/4 sleep and reduce REM latency.
At study end, REM sleep duration was slightly depressed, dropping to 77.9 minutes vs 83.8 minutes at placebo-baseline. This effect was largely due to a decrease of 11.0 minutes in the 60 mg ´14 day group. In contrast, the 30 mg ´14 day group saw an increase of 3.7 minutes of REM sleep over this period.
For the total study population, PSG sleep parameters were consistently improved by A-MQD compared with measures obtained at screening while on prior therapy. Both Total Sleep Time (TST) and Sleep Efficiency (SE) were significantly increased by study drug while Latency to Persistent Sleep (LPS) and Wake-time-after-SleepOnset (WASO) both trended downward (Table 1) . However, although some trends did emerge, A-MQD did not significantly impact PSG measures of sleep initiation and maintenance as compared with placebo baseline. Specifically, TST and SE increased while WASO and the Number of Awakenings (NAW) both decreased ( Table 1) .
The treatment subgroups demonstrated varying results on PSG outcome measures. The 30 mg ´14 day group was consistently improved relative to placebo baseline in all aspects of sleep: LPS, WASO, NAW, and REM sleep latency were reduced while SE and TST were increased (Figures 2 to 4) . Less consistent results for these measures were seen in 60 mg ´14 day group.
Subjective assessments
Subjective participant assessments of nighttime sleep indicated significant improvement with A-MQD (Table 2 and Figure 5 ). The entire participant population showed significant improvements in subjective sleep quality at both day 6 and day 15 (p = 0.0001, p £ 0.0001) relative to placebo-baseline values. Significance was maintained at day 6 for the 30 mg ´14 day group (p = 0.0254) and at day 15 for the 60 mg ´14 day groups (p = 0.0010). The study population reported sleeping for a mean of 30 minutes longer than at baseline at both the day 6 (p = 0.0691) and day 15 (p = 0.0286) time points. This increase in selfrated Number of Hours of Sleep was significant for the 30 mg ´14 day group (1.1 hours, p = 0.0313) and approached significance for the 60 mg ´14 day group (0.8 hours, p = 0.0625) at day 15.
Daytime alertness, as measured by the ESS, was impacted to a small, but significant degree for the study population as a whole at both day 6 (p = 0.015) and day 15 (p = 0.0150) ( Table 2 ), but no treatment group showed significant reduction in alertness as compared with placebo baseline.
Participants' assessments of their pain severity and their acceptance of, and relief provided by, the study drug indicate that A-MQD was an effective treatment for osteoarthritis pain (Table 3 ). Relative to placebo-baseline values, the BPI Average Pain scores were significantly improved for the total population (day 6, p = 0.0016; day 15, p £ 0.0001), the 30 mg ´14 day group (day 6, p = 0.0098; day 15, p = 0.0078) and the 60 mg ´14 day group (day 15, p = 0.0039) ( Table 3 ). The study population as a whole showed a significant increase in Acceptance of Current Therapy at day 6 (p = 0.0011) and day 15 (p = 0.0006) and indicated experiencing a significant improvement in Relief from Current Therapy (day 6 and day 15, p £ 0.001) relative to placebo-baseline values.
Neurocognitive battery
Treatment with A-MQD significantly enhanced cognition as compared with performance on prior analgesics and after a wash-out phase. When all treatment groups were combined (n = 31) significant improvement from screening (prior analgesics) was observed at day 15 for Letter Number Sequencing, Trails Making A&B, DSST, and RAVLT Immediate and Delayed Condition tests (p = 0.0237, p = 0.0004, p = 0.0039, p = 0.0231, p < 0.0001, and p < 0.0001, respectively). Trend improvement or no change was observed for other measures.
Significant improvements were also seen relative to placebo baseline on the RAVLT (p = 0.0136) and Trail Making part A (p = 0.0045) evaluations. Trend improvement or no change was observed for other measures. A thorough presentation of these results will be reported elsewhere.
Safety
A-MQD was generally safe and well tolerated. Side effects did not appear to exhibit a dose effect. Twentytwo patients experienced one or more adverse events, most of which were mild to moderate in severity. The most common adverse events (occurring in > 10 percent of all treated participants) were nausea (n = 10, 29 percent), sedation (n = 5, 15 percent), constipation (n = 5, 15 percent), vomiting (n = 4, 12 percent), and pruritus (n = 4, 12 percent). All of these events were consistent with the known effects of the study drug and had been observed in previous clinical trials.
Serious adverse events (SAEs) occurred in one participant (3 percent) while receiving 60 mg/d for eight days. The SAEs (experienced simultaneously) were severe sedation and unresponsiveness in this participant who was subsequently found to have previously undiagnosed hypothyroidism. The participant subsequently recovered from these adverse events. 
DISCUSSION
This single-center, placebo-baseline-controlled, single-treatment, single-blind study was designed to evaluate the impact of using A-MQD on objective and subjective measures of sleep as well as pain in participants with osteoarthritis complaining of sleep disturbances. Objective single-blind placebo baseline sleep characteristics confirmed the subjective perception of sleep disturbance due to chronic pain. The sleep fragmentation, low sleep efficiency, and poor subjective sleep quality in these chronic osteoarthritis participants were consistent with observations in other sleep studies in chronic pain participants. [16] [17] [18] Importantly, these sleep disturbances were present to an even greater degree during screening when participants were observed on their previous stable regimens of pain and sleep aids.
After withdrawal of all pain and sleep medication to establish baseline characteristics, participants were treated with either 30 or 60 mg/d of study drug for a period of 14 to 20 days. The results were very encouraging and intriguing: on the basis of objective and subjective outcome measures, the study drug improved both sleep and pain. Although improvements were not always statistically significant, likely owing to the small sample size, the overall trends were positive.
Treatment effects on sleep architecture included increases in the amount stage 2 and stage 3/4 sleep relative to both placebo baseline and screening (prior therapy) levels. In contrast to previous PSG studies of acute dosing with opioids at bedtime, A-MQD increased NREM sleep time when taken in the morning. REM latency was also significantly reduced with respect to both placebo baseline and screening observations. While minor, nonsignificant REM suppression vs baseline was seen with A-MQD, the time spent in REM sleep was markedly increased relative to the values seen at screening when participants were still taking their prior pain medication.
In addition, objective measures of sleep initiation and continuity as assessed in the participant population as a whole were improved by study drug when compared with placebo-baseline levels. TST and SE were increased while LPS, NAW, and WASO were reduced. Importantly, LPS, SE, TST, and WASO improvements were even greater when compared with screening values obtained when participants were on their previous stable regimens of pain and sleep medications.
Subjective assessments of sleep quality indicated that there was a clear perception of improved sleep with A-MQD. Perceived sleep quality and the subjective Number of Hours of Sleep were significantly improved across the total participant population. Again, these improvements were even greater when compared with screening (prior therapy) levels. Although daytime sleepiness as measured by ESS was significantly impaired relative to placebo baseline for the total population at both the day 6 and day 15, the actual ESS scores were within the range traditionally considered normal (ESS < 7). In view of the well-known sedative effects of morphine, it is reasonable to observe some drowsiness in this relatively short study with its limited time to tolerate this effect. Study results may indicate that A-MQD's extended release formulation may produce milder effects on alertness than an immediate release treatment.
A-MQD was also clearly effective as a pain medication. Significant improvements were seen at both days 6 and 15 on the BPI and participant ratings of the Acceptance of and Relief from Current Therapy. Scores on each of these scales also indicated improvements relative to screening values, indicating that the study drug was better at managing pain symptoms than the previous therapies utilized by participants.
Furthermore, results from the neurocognitive battery seemed to indicate that A-MQD may have enhanced cognition in this participant group relative to prior therapy. While the underlying biological underpinnings of these findings are unknown, it is possible that either the reduction of pain or the resumption of sleep may have accounted for the enhancement of mnemonic and attentional functioning. These results will be presented at greater length in a subsequent publication.
As mentioned earlier, a limitation of this study is its design as a placebo-baseline-controlled, single-treatment, single-blind study. However, the choice of a baseline control design was deliberate because of two concerns. First, there were significant ethical concerns that a separate placebo control arm design would potentially convey negative consequences to participants resulting from the cessation of pain relief therapy. Second, concerns about loss of study sensitivity linked to the expected heterogeneity of the study population were expected. These expectations of participant heterogeneity were supported by the need to increase the dose of study medication for those participants complaining of inadequate pain relief at day 6. We hypothesize that participants in the 30-mg group had mild to moderate chronic osteoarthritic pain, while participants who received 60 mg for any period of time could be considered to have moderate to severe pain, which was more difficult to control by the use of medication. This difference in pain level could be expected to significantly impact the variability of improvements in sleep seen across treatment groups, especially if the dose level did not reach therapeutic levels for an individual participant.
The extension of time under treatment for participants in the 60 mg ´14 day group added a temporal difference into study group comparisons. This change was introduced to allow the acute effects associated with transition to a new dose level to stabilize and permit equal amounts of time at a pain relieving dose. Nonetheless, it may be argued that the drug effect after two weeks (observed for participants in the 30 mg ´14 day and 60 mg ´8 day groups) may not be comparable to the drug effect seen after three weeks of treatment (60 mg ´14 day group). Morphine therapies are associated with the evolution of some level of tolerance to side effects, so the protocol change was expected to make the groups more comparable.
The results of this study suggest that A-MQD may be an effective treatment for participants with osteoarthritis pain and accompanying sleep disturbances. The improvements seen in all participants within measures of pain and sleep relative to untreated participants (placebo baseline) and participants with previous pain therapy (screening) may indicate that the previous therapies 1) were insufficient for the level of pain being experienced and 2) may have exacerbated the secondary sleeping difficulties experienced by participants. These data confirm the activity of A-MQD for the treatment of chronic moderate to severe osteoarthritis pain and support prior observations that with A-MQD pain therapy participants may expect improvements in the sleep disturbances commonly experienced by this participant population. More research could provide additional, helpful insights to inform clinicians' choices regarding the relationship between management of chronic pain and its associated sleep disturbances as well as further delineate A-MQD's ability to improve sleep and daytime functional outcomes in chronic pain populations. 
